Protocol Ledger

Academic / Institutional Sponsor · Consolidated Sponsor Hub

Charite University, Berlin, Germany: Clinical Trials & FDA Approval Profile

Charite University, Berlin, Germany (Global / Institutional) sponsors 28 reconciled interventional Phase II and Phase III ClinicalTrials.gov studies (2018 to 2026), including 9 active protocols (4 recruiting now), 6 completed protocols, and 0 all-time original FDA Drugs@FDA NDA and BLA approvals.

Track in Studio / Generate Client Brief ->
Early-Stop Rate vs National (13.8%)21.4%
Median Closed Enrollment vs National (145 pts)84 participants

Verified Sponsor Execution & Regulatory Ledger

Reconciled ClinicalTrials.gov v2 & Drugs@FDA Metrics for Charite University, Berlin, Germany
Sponsor MetricVerified Count / Rate
Phase II & III Protocols (2018 to 2026)28
Active Pipeline (Recruiting Now)9 (4)
Completed vs Stopped Early6 / 6 (21.4%)
Median Closed Actual Enrollment84 participants
Physical Hospital Site Disclosure100.0% named hospitals
FDA Drugs@FDA Original NDA/BLA Approvals0 (0 since 2018)

Top Partner U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Partnered With Charite University, Berlin, Germany
Hospital Research SiteLocationShared Protocols
Charité Universitätsmedizin BerlinBerlin7
Universitätsklinikum Hamburg-EppendorfHamburg2

Indexed Multi-Center Phase II & III Protocols

Representative ClinicalTrials.gov v2 Studies Sponsored by Charite University, Berlin, Germany
NCT IdentifierProtocol Brief TitlePhaseStatus
NCT07476729International Study for Treatment of Childhood Relapsed Precursor B-Cell ALL 2020 (IntReALL BCP 2020)Phase IIIRECRUITING
NCT04727073Spironolactone in the Treatment of Heart FailurePhase IIITERMINATED

Explore interactive annual charts and M&A subsidiary rollups in the Charite University, Berlin, Germany Interactive Dossier, benchmark peers in Immunology, Rheumatology, and Dermatology, or review the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI